Novartis R&D will ax 500 staffers, boost Boston in global realignment

Posted On 07 Nov 2013
By :

The global R&D shakeup at Novartis ($NVS) will hit U.S. operations as well as hundreds of staffers affected by the planned closure of its respiratory research center in Horsham, U.K. The Boston Globe reports this morning that Novartis told staffers on Wednesday that it will shutter a cancer research program in Emeryville, CA, as it cuts a total of about 500 research staffers from the payroll and adds 175 to its booming operations in the Boston biotech hub.

The company plans to close a dermatology center in Vienna and a biologics unit on its San Diego campus. Some scientists now working at Horsham, U.K., and Emeryville will relocate to the Cambridge, MA, area, where Novartis has a staff of 2,400.

Read the source article at fiercebiotech.com

About the Author

Leave a Reply